Balixafortide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种新型强效、选择性肽 CXCR4 拮抗剂，可干扰肿瘤保护性微环境并使肿瘤细胞对化疗敏感。

A novel potent, selective, peptidic CXCR4 antagonist that interferes with the tumor-protective microenvironment and sensitizes tumor cells to chemotherapy; induces efficient mobilization of HSPCs (hematopoietic stem and progenitor cell) in clinical trails.Blood Cancer Phase 2 Clinical.

Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Namalwa (IC50< 200 nM) and Jurkat (IC50 < 400 nM). Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC50 < 20 nM), Namalwa and Jurkat cells (IC50 < 10 nM).

Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability.

POL6326 | POL-6326

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

Cancer

Blood cancer

1051366-32-5

1782.029

C80H112N22O21S2

>98% (HPLC)

——

C[C@H]1C(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N1)=O)CO)=O)NC([C@H](C)N)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N4CCC[C@H]4C(N5CCC[C@H]5C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@@H](CC7=CNC=N7)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC8=CC=C(C=C8)O)=O)CCCNC(N)=N)=O)=O

Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide

(-20℃)

With Ice Pack

≥ 2 years